Compounds > gpi 1485
Page last updated: 2024-12-11

gpi 1485

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

GPI 1485: a neuroimmunophilin ligand that binds FK-506-binding proteins; may be useful as antiparkinson agent or for treating erectile dysfunction arising from post-prostatectomy [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

Cross-References

ID SourceID
PubMed CID9837656
CHEMBL ID4297382
SCHEMBL ID2006950
MeSH IDM0466706

Synonyms (36)

Synonym
AKOS015991368
186268-78-0
(2s)-1-(3,3-dimethyl-2-oxopentanoyl)pyrrolidine-2-carboxylic acid
gpi 1485
gpi-1485
AKOS016340704
(2s)-1-(3,3-dimethyl-2-oxopentanoyl)-2-pyrrolidinecarboxylic acid
l-proline, 1-(3,3-dimethyl-1,2-dioxopentyl)-
SCHEMBL2006950
1-(1,2-dioxo-3,3-dimethylpentyl)-2-pyrrolidine carboxylic acid, 2s
(2s)-1-(1,2-dioxo-3,3-dimethylpentyl)-2-pyrrolidinecarboxylic acid
unii-0709bvy57w
0709bvy57w ,
EG-0058
(2s)-1-(1, 2-dioxo-3,3-dimethylpentyl)-2-pyrrolidinecarboxylic acid
(2s)-1-(1.2-dioxo-3,3-dimethylpentyl)-2-pyrrolidinecarboxylic acid
(2s)-l-(1,2-dioxo-3,3-dimethylpentyl)-2-pyrrolidine-carboxylic acid
(2s)-1-(1,2-dioxo-3,3-dimethylpentyl) -2-pyrrolidinecarboxylic acid
(2s)-1(1,2-dioxo-3,3-dimethylpentyl)-2-pyrrolidinecarboxylic acid
(2s)-1-(1,2-dioxo-3 3-dimethylpentyl)-2-pyrrolidinecarboxylic acid
(2s)-1-(1,2-dioxo-3,3-dimethylpentyl) -2-pyrrolidine-carboxylic acid
FOPALECPEUVCTL-QMMMGPOBSA-N
(2s)-1-(1,2-dioxo-3,3-dimethylpentyl)-2-pyrrolidine-carboxylic acid
(2s) -1- (1,2-dioxo-3,3-dimethylpentyl) -2-pyrrolidine- carboxylic acid
(2s)-1-(l,2-dioxo-3,3-dimethylpentyl)-2-pyrrolidinecarboxylic acid
(2s)-1-(3,3-dimethyl-2-oxopentanoyl)-pyrrolidine-2-carboxylic acid
(s)-1-(3,3-dimethyl-2-oxopentanoyl)pyrrolidine-2-carboxylic acid
mfcd02179274
DB05814
EX-A7660
gm-1485
Q27236238
CHEMBL4297382
HY-136424
CS-0129294
(s)-1-(3,3-dimethyl-2-oxopentanoyl)pyrrolidine-2-carboxylicacid
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (5)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's3 (60.00)29.6817
2010's2 (40.00)24.3611
2020's0 (0.00)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 17.40

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be moderate demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index17.40 (24.57)
Research Supply Index2.20 (2.92)
Research Growth Index4.42 (4.65)
Search Engine Demand Index10.37 (26.88)
Search Engine Supply Index2.00 (0.95)

This Compound (17.40)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials3 (60.00%)5.53%
Reviews1 (20.00%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other1 (20.00%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]
SubstanceRelationship StrengthStudiesTrialsClassesRoles
creatine
[no description available]		3.4311glycine derivative;
guanidines;
zwitterion		geroprotector;
human metabolite;
mouse metabolite;
neuroprotective agent;
nutraceutical
tacrolimus
Tacrolimus: A macrolide isolated from the culture broth of a strain of Streptomyces tsukubaensis that has strong immunosuppressive activity in vivo and prevents the activation of T-lymphocytes in response to antigenic or mitogenic stimulation in vitro.. tacrolimus (anhydrous) : A macrolide lactam containing a 23-membered lactone ring, originally isolated from the fermentation broth of a Japanese soil sample that contained the bacteria Streptomyces tsukubaensis.		9.2575macrolide lactambacterial metabolite;
immunosuppressive agent
coenzyme q10
coenzyme Q10: Ubiquinone ring with a chain of 10 isoprene units; redox equilibrium with ubiqunol serving in mitochondrial inner membrane to transfer electrons; presence during reconstitution of acetylcholine receptor into phospholipid vesicles yields vesicles active in catalyzing carbamylcholine-sensitive Na+ flux; coenzyme Q10 depletion has been noted with use of statins. coenzyme Q10 : A ubiquinone having a side chain of 10 isoprenoid units. In the naturally occurring isomer, all isoprenyl double bonds are in the E- configuration.		5.7722ubiquinonesantioxidant;
ferroptosis inhibitor;
human metabolite
ubiquinone
Ubiquinone: A lipid-soluble benzoquinone which is involved in ELECTRON TRANSPORT in mitochondrial preparations. The compound occurs in the majority of aerobic organisms, from bacteria to higher plants and animals.		6.4233
minocycline
Minocycline: A TETRACYCLINE analog, having a 7-dimethylamino and lacking the 5 methyl and hydroxyl groups, which is effective against tetracycline-resistant STAPHYLOCOCCUS infections.. minocycline : A tetracycline analogue having a dimethylamino group at position 7 and lacking the methyl and hydroxy groups at position 5.		3.4311
ConditionIndicatedRelationship StrengthStudiesTrials
Disease Exacerbation
[description not available]		07.5244
Idiopathic Parkinson Disease
[description not available]		010.57109
Parkinson Disease
A progressive, degenerative neurologic disease characterized by a TREMOR that is maximal at rest, retropulsion (i.e. a tendency to fall backwards), rigidity, stooped posture, slowness of voluntary movements, and a masklike facial expression. Pathologic features include loss of melanin containing neurons in the substantia nigra and other pigmented nuclei of the brainstem. LEWY BODIES are present in the substantia nigra and locus coeruleus but may also be found in a related condition (LEWY BODY DISEASE, DIFFUSE) characterized by dementia in combination with varying degrees of parkinsonism. (Adams et al., Principles of Neurology, 6th ed, p1059, pp1067-75)		112.57109
Ambulation Difficulty
[description not available]		03.4311
Cerebral Infarction, Middle Cerebral Artery
[description not available]		02.0710
Disease Models, Animal
Naturally-occurring or experimentally-induced animal diseases with pathological processes analogous to human diseases.		02.0710
Infarction, Middle Cerebral Artery
NECROSIS occurring in the MIDDLE CEREBRAL ARTERY distribution system which brings blood to the entire lateral aspects of each CEREBRAL HEMISPHERE. Clinical signs include impaired cognition; APHASIA; AGRAPHIA; weak and numbness in the face and arms, contralaterally or bilaterally depending on the infarction.		02.0710
Impotence
[description not available]		02.9310
Erectile Dysfunction
The inability in the male to have a PENILE ERECTION due to psychological or organ dysfunction.		02.9310
Bilateral Headache
[description not available]		07.4644
Headache
The symptom of PAIN in the cranial region. It may be an isolated benign occurrence or manifestation of a wide variety of HEADACHE DISORDERS.		07.4644
Nausea
An unpleasant sensation in the stomach usually accompanied by the urge to vomit. Common causes are early pregnancy, sea and motion sickness, emotional stress, intense pain, food poisoning, and various enteroviruses.		07.4644